Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Transcept Pharma Promotes CFO Thomas Soloway To COO

RELATED NEWS
Trade TSPT now with 

Transcept Pharmaceuticals (TSPT: Quote) said Tuesday that it has appointed Thomas Soloway as the executive vice president and chief operating officer. Soloway joined Transcept as a co-founder in 2002 and served previously as Senior Vice President, Operations and Chief Financial Officer prior to this promotion.

All senior executives of the company, except Chief Scientific Officer and Co-Founder Nikhilesh Singh, will hereafter report to Soloway. Singh will continue to report to President and Chief Executive Officer Glenn Oclassen.

Click here to receive FREE breaking news email alerts for Transcept Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.